| Devatis AG - Levodopa / Benserazid Devatis 250 mg (200 mg + 50 mg), Tabletten | | 68472 | | 03 | | Levodopa / Benserazid Devatis 250 mg (200 mg + 50 mg) | | Tabletten | | N04BA02 | | Levodopa und Decarboxylasehemmer | | 01.12.2021 | | |
| | Composition | | benserazidum 50 mg ut benserazidi hydrochloridum, levodopum 200 mg, natrii docusas, E 172 (rubrum), ethylcellulosum, silica colloidalis anhydrica, cellulosum microcristallinum, amylum pregelificatum, mannitolum, calcii hydrogenophosphas, crospovidonum, magnesii stearas, pro compresso corresp. natrium 0.01035 mg. | | Packungsbestandteile | | Comprimés | | | | | Principe actif | Concentr. |
|---|
| Benserazide | 50 mg | | Levodopa | 200 mg |
| | BAG: Principe actif | Concentr. |
|---|
| Benserazide | 50 mg | | Levodopa | 200 mg |
| | | | Agents auxilliaires | | informations additionels |
|---|
| (Rubrum) | | | | Amylum Pregelificatum | | | | Calcium Hydrogenophosphate | | | | Cellulosum Microcristallinum | | | | Crospovidonum | | | | E 172 | | color. | | Ethylcellulosum | | | | Magnesii Stearas | | | | Mannitol | | | | Natrii Docusas | | | | Pro Compresso | | | | Silica Colloidalis Anhydrica | | |
| |
| |
|
